HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price

Key Points

• HC Wainwright has decreased its price target for Arvinas (NASDAQ:ARVN) from $24.00 to $18.00, while maintaining a "buy" rating, suggesting a potential upside of 195.57%.
• Multiple analysts have revised their ratings and price targets for Arvinas, with estimates ranging as low as $9.00 and as high as $19.76, reflecting a consensus average rating of "Moderate Buy."
• Arvinas reported a significant revenue decline of 70.7% year-over-year, with a negative net margin and an earnings per share estimate of -3.81 for the current fiscal year.

Arvinas (NASDAQ:ARVN - Free Report) had its target price reduced by HC Wainwright from $24.00 to $18.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently issued reports on ARVN. Morgan Stanley decreased their price target on Arvinas from $12.00 to $11.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Guggenheim cut their price objective on Arvinas from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday. Truist Financial restated a "hold" rating and issued a $11.00 price objective (down from $21.00) on shares of Arvinas in a research report on Monday, May 5th. TD Cowen cut Arvinas from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, Barclays cut their price objective on Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $19.76.

Arvinas Stock Up 4.8%

Shares of Arvinas stock traded up $0.30 on Thursday, reaching $6.59. 2,217,168 shares of the stock were exchanged, compared to its average volume of 2,196,073. Arvinas has a twelve month low of $5.90 and a twelve month high of $29.61. The firm has a market capitalization of $483.84 million, a price-to-earnings ratio of -6.52 and a beta of 2.22. The business has a 50 day moving average price of $7.52 and a two-hundred day moving average price of $9.86.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.03. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%. The company had revenue of $22.40 million during the quarter, compared to the consensus estimate of $34.42 million. During the same period in the previous year, the company posted ($0.49) earnings per share. Arvinas's revenue for the quarter was down 70.7% on a year-over-year basis. Research analysts forecast that Arvinas will post -3.81 EPS for the current year.

Insider Transactions at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the completion of the sale, the chief financial officer directly owned 164,401 shares in the company, valued at $1,251,091.61. This represents a 3.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.73% of the stock is currently owned by insiders.

Institutional Trading of Arvinas

Several large investors have recently added to or reduced their stakes in ARVN. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas in the 4th quarter valued at $28,000. GAMMA Investing LLC lifted its stake in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock valued at $300,000 after purchasing an additional 4,175 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Arvinas by 965.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock valued at $33,000 after purchasing an additional 4,219 shares during the last quarter. CWM LLC lifted its stake in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after purchasing an additional 7,300 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Arvinas in the 2nd quarter valued at $74,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.